Improvement of the Effectiveness of Antiviral Treatment of Patients with Chronic Hepatitis C and Concomitant Diabetes Mellitus Type II using Alpha-Lipoic Acid and Lactulose
HTML
PDF

Keywords

chronic hepatitis C
viral load
cytokines
diabetes mellitus

Abstract

Imbalance of pro-inflammatory and anti-inflammatory cytokines was detected in 104 examined the patients with chronic hepatitis C. These changes were the most significant in patients with concomitant diabetes mellitus (DM) type II. Achievement of sustained viral response (SVR) under the influence of antiviral therapy depends on the state of cytokines system. This was evidenced by the detected correlation relationship between the levels of viral load (VL) in patients with concomitant diabetes mellitus type II, namely, direct weak one between IL-4 and VL (r=0.21) and reverse weak one between the level of IL-2 and VL (r=-0.04). Virus elimination rate and frequency influenced by anti-viral therapy (AVT) depends on the balance of pro-inflammatory and anti-inflammatory cytokines. This was shown in the research by detection of direct medium correlation relationship between VL and IL-4 (r= 0.31) and reverse medium correlation relationship between VL and IL-2 (r= -0.45).
https://doi.org/10.21802/gmj.2016.4.15
HTML
PDF

References

Golubovskaya OA, Kuliesh OV. [The course of chronic hepatitis С against the background metabolic risk factors as the components of metabolic syndrome and modern approaches to its correction]. Suchasna hastroenterolohiia. 2014;5 (79):93–97

Golubovska OA, Kondratiuk OL. Pozapechinkovi proiavy chronichnoho hepatytu C ta iikh vplyv na osoblyvosti perebihu zakhvoriuvannia ta likuvannia (ohliad literatury). Suchasni infektsii. 2011;1:96–103

Ponezheva JB, Nagoev BS, Dubinina NV, Kalyuzhin OV. [Clinical immunological characteristics of chronic hepatitis C in dependence on virus genotype]. Immunopathology, allergology, infectology. 2011;2:26–30

Koliush OI. Immunologicheskie meckanizmy v patogeneze khronicheskogo virusnogo hepatita C. Suchasni infektsii. 2001;3:110–115

Romanova MA. Kliniko-patogeneticheskoe znachenie insulinorezistentnosti pri khronicheskom hepatite C. Thesis. Saint Petersburg: 2011

Popova LL, Konstantinov DYu. Profil tsitokinov v plazme krovi patsientov s khronicheskom hepatitom C v zavisimosti ot virusologicheskoi aktivnosti (HCV RNA + i HCV RNA-). Tsitokiny i vospalenie. 2015;14 (2):97–100

Simbirtsev AS. Tsitokiny: klassifikatsiya i biologicheskie funktsii. Tsitokiny i vospalenie. 2004;2:16–19

Sitnikov IG, Ryzhkina AV, Bokhonov MS. Optimizatsiya terapii khronicheskogo hepatita C protekayushchego s zhirovym porazheniem pecheni. Infektsionnye bolezni. 2010;8 (2):22–26

Sklyar LP, Markelova EV, Gorelova IS. [Efficiency of immunocorrection in chronic viral hepatitis c patients treated by antivirals]. Infektsiya i immunitet. 2013;3 (1):59–64

Sotska YaA, Frolov VM, Kruglova OV. Influence of nucleinas on cytokine blood profile of the patients with chronic viral hepatitis C with low degree activity. Ukraiinskyi morfolohichnyi almanakh. 2011;9(2):83–86

Moroz LV, Ocheredko OM, Shkondyna OF, et al. Suchasna model perebihu khronichnoho hepatytu C zalezhno vid henotypu virusu. Infektsiini khvoroby. 2009;1:14–20

Ushenina LA, Ryabokon OV. [Clinical-biochemical and morphological features of chronic hepatitis C at infectious different genotypes HCV]. Patolohiia. 2009;6 (1):86–89

Fadeenko GD, Kravchenko NA, Jarmish NV. [Factors of liver fibrosis progression]. Suchasna hastroenterolohiia. 2007;1:74–80

Gural AL, Marievskiy VF, Sergeyeva TA, et al. [Characteristics and trends of hepatitis’ C epidemic process in Ukraine]. Profilaktychna medytsyna. 2011;1:9–17

Cherenova VK, Galimzyanov KhM, Kudriavtsev VA. Khronicheskiy hepatit C: kliniko-epidemiologicheskie aspekty. Epidemiologiya i vaktsinoprofilaktika. 2010;1:58–63

Shved MI, Mazur LP. Porushennia lipidnoho obminu, perekysnoho okyslennia lipidiv ta imunnoho status i efektyvnist iikh korektsii vobenzymom y khvorykh na tsukrovyi diabet II typu z morfo-funktsionalnymy zminamy pechinky. Galic’kij likars’kij visnik. 2005;12(3):90–94

Yushchuk ND, Znoiko OO, Dudina KR. Effektivnost protivovirusnoi terapii u bolnykh khronicheskim hepatitom C, infitsirovannykh virusami hepatita C rekombinantnykh variantov. Terapevticheskiy arkhiv. 2016;88 (6):101–105. DOI: http://doi.org/10.17116/terarkh2016886101-105

Berenguer M. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol. 2000;32 (4):673–684. DOI: http://doi.org/10.1016/S0168-8278(00)80231-7

Castera L, Vergniol J, Foucher J. Prospective comparison of transient elastography, Fibrotest, APRI and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005;128:343–350. DOI: http://doi.org/10.1053/j.gastro.2004.11.018 [PMid: 15685546]

Dubuisson J. Hepatitis C virus proteins. World J Gastroenterol. 2007;17(13):2406–2415. DOI: http://doi.org/10.3748/wjg.v13.i17.2406 [PMCid: PMC4146758]

Sanyal AJ, Chand N, Comar K, et al. Hyperinsulinemia blocks the inhibition of hepatitis C virus (HCV) replication by interferon: a potential mechanism for failure of interferon therapy in subjects with HCV and nonalcoholic fatty liver disease. Hepatology. 2004;40:179A

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Downloads

Download data is not yet available.